Nantahala Capital Management
Latest statistics and disclosures from Nantahala Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are IWM, IWM, LLY, LLY, SLNO, and represent 31.83% of Nantahala Capital Management's stock portfolio.
- Added to shares of these 10 stocks: IWM (+$61M), LLY (+$54M), PTON (+$35M), SLNO (+$27M), SVRA (+$14M), TBBK (+$13M), OPTN (+$12M), IMAX (+$10M), EGRX (+$9.5M), EB (+$7.7M).
- Started 21 new stock positions in AVDL, ETON, CNTA, ELDN, KRYS, Kiora Pharmaceuticals, IRON, Nikola Corp, LXRX, Strata Skin Sciences. BCOV, GORV, SRZN, CNTX, VSTM, TBBK, BNTC, EB, ATXS, OCUL, RPHM.
- Reduced shares in these 10 stocks: XBI (-$67M), , CASH (-$27M), IYR (-$27M), LYRA (-$18M), RDVT (-$17M), DYN (-$12M), GDEN (-$9.9M), DXPE (-$7.6M), TARS (-$5.5M).
- Sold out of its positions in AVTE, ARHS, PLCE, COST, CUE, DYN, GDEN, IYR, KTRA, Kiora Pharmaceuticals. LYRA, MTTR, Par Technology Corp, AGS, Strata Skin Sciences, TARS, Gamida Cell, NAMS.
- Nantahala Capital Management was a net buyer of stock by $57M.
- Nantahala Capital Management has $3.4B in assets under management (AUM), dropping by 94.86%.
- Central Index Key (CIK): 0001472322
Tip: Access up to 7 years of quarterly data
Positions held by Nantahala Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Nantahala Capital Management
Nantahala Capital Management holds 240 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ishares Tr Russell 2000 Etf (IWM) | 9.8 | $335M | +22% | 1.7M | 202.89 |
|
| Ishares Tr Russell 2000 Etf (IWM) | 9.8 | $335M | +22% | 1.7M | 202.89 |
|
| Eli Lilly & Co. Put Option (LLY) | 4.2 | $145M | +60% | 160k | 905.38 |
|
| Eli Lilly & Co. Put Option (LLY) | 4.2 | $145M | +60% | 160k | 905.38 |
|
| Soleno Therapeutics (SLNO) | 3.7 | $126M | +27% | 3.1M | 40.80 |
|
| Soleno Therapeutics (SLNO) | 3.7 | $126M | +27% | 3.1M | 40.80 |
|
| Establishment Labs Holdings Ord (ESTA) | 3.3 | $114M | 2.5M | 45.44 |
|
|
| Establishment Labs Holdings Ord (ESTA) | 3.3 | $114M | 2.5M | 45.44 |
|
|
| Spdr Ser Tr S&p Biotech (XBI) | 3.3 | $113M | -37% | 1.2M | 92.71 |
|
| Spdr Ser Tr S&p Biotech (XBI) | 3.3 | $113M | -37% | 1.2M | 92.71 |
|
| Peloton Interactive Cl A Com (PTON) | 1.9 | $64M | +117% | 19M | 3.38 |
|
| Peloton Interactive Cl A Com (PTON) | 1.9 | $64M | +117% | 19M | 3.38 |
|
| Grand Canyon Education Put Option (LOPE) | 1.6 | $56M | 400k | 139.91 |
|
|
| Grand Canyon Education Put Option (LOPE) | 1.6 | $56M | 400k | 139.91 |
|
|
| Imax Corp Cad (IMAX) | 1.4 | $47M | +27% | 2.8M | 16.77 |
|
| Imax Corp Cad (IMAX) | 1.4 | $47M | +27% | 2.8M | 16.77 |
|
| Evolus (EOLS) | 0.9 | $32M | 2.9M | 10.85 |
|
|
| Evolus (EOLS) | 0.9 | $32M | 2.9M | 10.85 |
|
|
| Bioventus Com Cl A (BVS) | 0.9 | $31M | -8% | 5.3M | 5.75 |
|
| Bioventus Com Cl A (BVS) | 0.9 | $31M | -8% | 5.3M | 5.75 |
|
| Meta Financial (CASH) | 0.9 | $31M | -47% | 541k | 56.57 |
|
| Meta Financial (CASH) | 0.9 | $31M | -47% | 541k | 56.57 |
|
| Hilton Grand Vacations (HGV) | 0.8 | $27M | 669k | 40.43 |
|
|
| Hilton Grand Vacations (HGV) | 0.8 | $27M | 669k | 40.43 |
|
|
| Savara (SVRA) | 0.6 | $21M | +198% | 5.2M | 4.03 |
|
| Savara (SVRA) | 0.6 | $21M | +198% | 5.2M | 4.03 |
|
| America's Car-Mart (CRMT) | 0.6 | $19M | 312k | 60.21 |
|
|
| America's Car-Mart (CRMT) | 0.6 | $19M | 312k | 60.21 |
|
|
| Rumbleon Com Cl B (RMBL) | 0.5 | $18M | 4.4M | 4.10 |
|
|
| Rumbleon Com Cl B (RMBL) | 0.5 | $18M | 4.4M | 4.10 |
|
|
| Keros Therapeutics (KROS) | 0.5 | $17M | +28% | 379k | 45.70 |
|
| Keros Therapeutics (KROS) | 0.5 | $17M | +28% | 379k | 45.70 |
|
| Amneal Pharmaceuticals Com Stk Cl A (AMRX) | 0.5 | $17M | 2.7M | 6.35 |
|
|
| Amneal Pharmaceuticals Com Stk Cl A (AMRX) | 0.5 | $17M | 2.7M | 6.35 |
|
|
| Abeona Therapeutics Com New (ABEO) | 0.5 | $17M | +40% | 4.0M | 4.24 |
|
| Abeona Therapeutics Com New (ABEO) | 0.5 | $17M | +40% | 4.0M | 4.24 |
|
| Eagle Pharmaceuticals (EGRX) | 0.5 | $17M | +135% | 3.0M | 5.60 |
|
| Eagle Pharmaceuticals (EGRX) | 0.5 | $17M | +135% | 3.0M | 5.60 |
|
| Optinose (OPTN) | 0.4 | $14M | +442% | 13M | 1.07 |
|
| Optinose (OPTN) | 0.4 | $14M | +442% | 13M | 1.07 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.4 | $13M | -2% | 986k | 13.22 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.4 | $13M | -2% | 986k | 13.22 |
|
| Uniqure Nv SHS (QURE) | 0.4 | $13M | -13% | 2.9M | 4.48 |
|
| Uniqure Nv SHS (QURE) | 0.4 | $13M | -13% | 2.9M | 4.48 |
|
| Rezolute Com New (RZLT) | 0.4 | $13M | 3.0M | 4.30 |
|
|
| Rezolute Com New (RZLT) | 0.4 | $13M | 3.0M | 4.30 |
|
|
| Ban (TBBK) | 0.4 | $13M | NEW | 338k | 37.76 |
|
| Ban (TBBK) | 0.4 | $13M | NEW | 338k | 37.76 |
|
| Reservoir Media (RSVR) | 0.4 | $12M | 1.6M | 7.90 |
|
|
| Reservoir Media (RSVR) | 0.4 | $12M | 1.6M | 7.90 |
|
|
| Zevra Therapeutics Com New (ZVRA) | 0.3 | $12M | 2.4M | 4.90 |
|
|
| Zevra Therapeutics Com New (ZVRA) | 0.3 | $12M | 2.4M | 4.90 |
|
|
| Payoneer Global (PAYO) | 0.3 | $12M | -2% | 2.1M | 5.54 |
|
| Assertio Holdings Com New (ASRT) | 0.3 | $12M | 9.3M | 1.24 |
|
|
| Assertio Holdings Com New (ASRT) | 0.3 | $12M | 9.3M | 1.24 |
|
|
| Tela Bio (TELA) | 0.3 | $12M | +122% | 2.4M | 4.70 |
|
| Tela Bio (TELA) | 0.3 | $12M | +122% | 2.4M | 4.70 |
|
| Red Violet (RDVT) | 0.3 | $12M | -59% | 453k | 25.40 |
|
| Red Violet (RDVT) | 0.3 | $12M | -59% | 453k | 25.40 |
|
| Codexis (CDXS) | 0.3 | $11M | -18% | 3.6M | 3.10 |
|
| Codexis (CDXS) | 0.3 | $11M | -18% | 3.6M | 3.10 |
|
| Enova Intl (ENVA) | 0.3 | $10M | -8% | 165k | 62.25 |
|
| Enova Intl (ENVA) | 0.3 | $10M | -8% | 165k | 62.25 |
|
| Payoneer Global (PAYO) | 0.3 | $9.9M | -2% | 1.8M | 5.54 |
|
| Aura Biosciences (AURA) | 0.3 | $9.6M | -3% | 1.3M | 7.56 |
|
| Aura Biosciences (AURA) | 0.3 | $9.6M | -3% | 1.3M | 7.56 |
|
| Viemed Healthcare (VMD) | 0.3 | $9.4M | -7% | 1.4M | 6.55 |
|
| Viemed Healthcare (VMD) | 0.3 | $9.4M | -7% | 1.4M | 6.55 |
|
| Syndax Pharmaceuticals (SNDX) | 0.3 | $9.3M | -2% | 453k | 20.53 |
|
| Syndax Pharmaceuticals (SNDX) | 0.3 | $9.3M | -2% | 453k | 20.53 |
|
| Immatics SHS (IMTX) | 0.3 | $9.2M | 788k | 11.62 |
|
|
| Immatics SHS (IMTX) | 0.3 | $9.2M | 788k | 11.62 |
|
|
| Tourmaline Bio (TRML) | 0.3 | $9.0M | 701k | 12.86 |
|
|
| Tourmaline Bio (TRML) | 0.3 | $9.0M | 701k | 12.86 |
|
|
| Vanda Pharmaceuticals (VNDA) | 0.3 | $9.0M | +57% | 1.6M | 5.65 |
|
| Vanda Pharmaceuticals (VNDA) | 0.3 | $9.0M | +57% | 1.6M | 5.65 |
|
| Elutia Cl A Com (ELUT) | 0.3 | $8.9M | +8% | 1.8M | 4.96 |
|
| Elutia Cl A Com (ELUT) | 0.3 | $8.9M | +8% | 1.8M | 4.96 |
|
| eHealth (EHTH) | 0.3 | $8.7M | 1.9M | 4.53 |
|
|
| eHealth (EHTH) | 0.3 | $8.7M | 1.9M | 4.53 |
|
|
| Herbalife Com Shs Call Option (HLF) | 0.2 | $8.3M | +60% | 800k | 10.39 |
|
| Herbalife Com Shs Call Option (HLF) | 0.2 | $8.3M | +60% | 800k | 10.39 |
|
| Eventbrite Com Cl A (EB) | 0.2 | $7.7M | NEW | 1.6M | 4.84 |
|
| Eventbrite Com Cl A (EB) | 0.2 | $7.7M | NEW | 1.6M | 4.84 |
|
| Luxfer Hldgs SHS (LXFR) | 0.2 | $7.0M | -11% | 604k | 11.59 |
|
| Luxfer Hldgs SHS (LXFR) | 0.2 | $7.0M | -11% | 604k | 11.59 |
|
| Industrial Logistics Pptys T Com Shs Ben Int (ILPT) | 0.2 | $6.9M | 1.9M | 3.68 |
|
|
| Industrial Logistics Pptys T Com Shs Ben Int (ILPT) | 0.2 | $6.9M | 1.9M | 3.68 |
|
|
| Ocular Therapeutix (OCUL) | 0.2 | $6.8M | NEW | 1.0M | 6.84 |
|
| Ocular Therapeutix (OCUL) | 0.2 | $6.8M | NEW | 1.0M | 6.84 |
|
| Noodles & Co Com Cl A (NDLS) | 0.2 | $6.8M | +6% | 4.3M | 1.58 |
|
| Noodles & Co Com Cl A (NDLS) | 0.2 | $6.8M | +6% | 4.3M | 1.58 |
|
| Rmr Group Cl A (RMR) | 0.2 | $6.8M | -13% | 301k | 22.60 |
|
| Rmr Group Cl A (RMR) | 0.2 | $6.8M | -13% | 301k | 22.60 |
|
| Disc Medicine (IRON) | 0.2 | $6.8M | NEW | 150k | 45.07 |
|
| Disc Medicine (IRON) | 0.2 | $6.8M | NEW | 150k | 45.07 |
|
| Alta Equipment Group Common Stock (ALTG) | 0.2 | $6.7M | +108% | 838k | 8.04 |
|
| Alta Equipment Group Common Stock (ALTG) | 0.2 | $6.7M | +108% | 838k | 8.04 |
|
| Cogent Biosciences (COGT) | 0.2 | $6.7M | 791k | 8.43 |
|
|
| Cogent Biosciences (COGT) | 0.2 | $6.7M | 791k | 8.43 |
|
|
| Mineralys Therapeutics (MLYS) | 0.2 | $6.2M | +60% | 533k | 11.70 |
|
| Mineralys Therapeutics (MLYS) | 0.2 | $6.2M | +60% | 533k | 11.70 |
|
| Astria Therapeutics (ATXS) | 0.2 | $6.1M | NEW | 675k | 9.10 |
|
| Astria Therapeutics (ATXS) | 0.2 | $6.1M | NEW | 675k | 9.10 |
|
| Benitec Biopharma Com New (BNTC) | 0.2 | $5.9M | NEW | 841k | 6.99 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.2 | $5.3M | 1.5M | 3.48 |
|
|
| Vistagen Therapeutics Ord (VTGN) | 0.2 | $5.3M | 1.5M | 3.48 |
|
|
| One Group Hospitality In (STKS) | 0.1 | $5.1M | +119% | 1.2M | 4.25 |
|
| One Group Hospitality In (STKS) | 0.1 | $5.1M | +119% | 1.2M | 4.25 |
|
| Nektar Therapeutics (NKTR) | 0.1 | $5.1M | +65% | 4.1M | 1.24 |
|
| Nektar Therapeutics (NKTR) | 0.1 | $5.1M | +65% | 4.1M | 1.24 |
|
| Inspiremd (NSPR) | 0.1 | $5.1M | 2.0M | 2.50 |
|
|
| Inspiremd (NSPR) | 0.1 | $5.1M | 2.0M | 2.50 |
|
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 0.1 | $4.9M | NEW | 350k | 14.06 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 0.1 | $4.9M | NEW | 350k | 14.06 |
|
| Dxp Enterprises Com New (DXPE) | 0.1 | $4.7M | -61% | 103k | 45.84 |
|
| Dxp Enterprises Com New (DXPE) | 0.1 | $4.7M | -61% | 103k | 45.84 |
|
| Neuropace (NPCE) | 0.1 | $4.7M | -20% | 617k | 7.56 |
|
| Neuropace (NPCE) | 0.1 | $4.7M | -20% | 617k | 7.56 |
|
| Reading Intl Cl A (RDI) | 0.1 | $4.6M | -4% | 3.2M | 1.42 |
|
| Reading Intl Cl A (RDI) | 0.1 | $4.6M | -4% | 3.2M | 1.42 |
|
| Cellectar Biosciences Com New (CLRB) | 0.1 | $4.6M | -2% | 1.8M | 2.50 |
|
| Cellectar Biosciences Com New (CLRB) | 0.1 | $4.6M | -2% | 1.8M | 2.50 |
|
| Zynex (ZYXI) | 0.1 | $4.6M | 490k | 9.32 |
|
|
| Zynex (ZYXI) | 0.1 | $4.6M | 490k | 9.32 |
|
|
| NN (NNBR) | 0.1 | $4.4M | +3% | 1.5M | 3.00 |
|
| NN (NNBR) | 0.1 | $4.4M | +3% | 1.5M | 3.00 |
|
| Dhi (DHX) | 0.1 | $4.3M | +5% | 2.1M | 2.09 |
|
| Dhi (DHX) | 0.1 | $4.3M | +5% | 2.1M | 2.09 |
|
| Perella Weinberg Partners Class A Com (PWP) | 0.1 | $4.3M | +35% | 266k | 16.25 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.1 | $4.1M | NEW | 450k | 9.03 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.1 | $4.1M | NEW | 450k | 9.03 |
|
| Gaia Cl A (GAIA) | 0.1 | $4.0M | 915k | 4.41 |
|
|
| Gaia Cl A (GAIA) | 0.1 | $4.0M | 915k | 4.41 |
|
|
| Context Therapeutics (CNTX) | 0.1 | $3.9M | NEW | 1.9M | 2.00 |
|
| Context Therapeutics (CNTX) | 0.1 | $3.9M | NEW | 1.9M | 2.00 |
|
| Lexicon Pharmaceuticals Com New (LXRX) | 0.1 | $3.9M | NEW | 2.3M | 1.68 |
|
| Lexicon Pharmaceuticals Com New (LXRX) | 0.1 | $3.9M | NEW | 2.3M | 1.68 |
|
| Silence Therapeutics Ads (SLN) | 0.1 | $3.8M | 200k | 19.00 |
|
|
| Silence Therapeutics Ads (SLN) | 0.1 | $3.8M | 200k | 19.00 |
|
|
| Theratechnologies Com New (THTX) | 0.1 | $3.8M | 2.7M | 1.40 |
|
|
| Theratechnologies Com New (THTX) | 0.1 | $3.8M | 2.7M | 1.40 |
|
|
| Aytu Biopharma (AYTU) | 0.1 | $3.2M | 1.1M | 2.92 |
|
|
| Aytu Biopharma (AYTU) | 0.1 | $3.2M | 1.1M | 2.92 |
|
|
| Brightcove (BCOV) | 0.1 | $3.1M | NEW | 1.3M | 2.37 |
|
| Brightcove (BCOV) | 0.1 | $3.1M | NEW | 1.3M | 2.37 |
|
| Eton Pharmaceuticals (ETON) | 0.1 | $3.1M | NEW | 941k | 3.29 |
|
| Eton Pharmaceuticals (ETON) | 0.1 | $3.1M | NEW | 941k | 3.29 |
|
| Achieve Life Sciences (ACHV) | 0.1 | $3.1M | 654k | 4.70 |
|
|
| Achieve Life Sciences (ACHV) | 0.1 | $3.1M | 654k | 4.70 |
|
|
| Dariohealth Corp Com New (DRIO) | 0.1 | $2.8M | -9% | 2.4M | 1.19 |
|
| Dariohealth Corp Com New (DRIO) | 0.1 | $2.8M | -9% | 2.4M | 1.19 |
|
| Fossil (FOSL) | 0.1 | $2.7M | +45% | 1.9M | 1.42 |
|
| Fossil (FOSL) | 0.1 | $2.7M | +45% | 1.9M | 1.42 |
|
| Neurogene (NGNE) | 0.1 | $2.6M | 72k | 36.39 |
|
|
| Neurogene (NGNE) | 0.1 | $2.6M | 72k | 36.39 |
|
|
| Envveno Medical (NVNO) | 0.1 | $2.5M | -3% | 478k | 5.25 |
|
| Envveno Medical (NVNO) | 0.1 | $2.5M | -3% | 478k | 5.25 |
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $2.3M | 1.8M | 1.32 |
|
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $2.3M | 1.8M | 1.32 |
|
|
| Xtant Med Hldgs Com New (XTNT) | 0.1 | $2.3M | -10% | 3.6M | 0.63 |
|
| Xtant Med Hldgs Com New (XTNT) | 0.1 | $2.3M | -10% | 3.6M | 0.63 |
|
| Perella Weinberg Partners Class A Com (PWP) | 0.1 | $2.2M | +35% | 135k | 16.25 |
|
| Conn's (CONN) | 0.1 | $2.2M | +11% | 2.0M | 1.10 |
|
| Conn's (CONN) | 0.1 | $2.2M | +11% | 2.0M | 1.10 |
|
| Surrozen Com New (SRZN) | 0.1 | $2.0M | NEW | 187k | 10.95 |
|
| Surrozen Com New (SRZN) | 0.1 | $2.0M | NEW | 187k | 10.95 |
|
| Talphera Com New (TLPH) | 0.1 | $1.8M | 2.0M | 0.89 |
|
|
| Talphera Com New (TLPH) | 0.1 | $1.8M | 2.0M | 0.89 |
|
|
| Scully Royalty Com Shs (SRL) | 0.0 | $1.7M | 239k | 7.12 |
|
|
| Scully Royalty Com Shs (SRL) | 0.0 | $1.7M | 239k | 7.12 |
|
|
| Mediaalpha Cl A (MAX) | 0.0 | $1.6M | -17% | 124k | 13.17 |
|
| Mediaalpha Cl A (MAX) | 0.0 | $1.6M | -17% | 124k | 13.17 |
|
| Spar (SGRP) | 0.0 | $1.6M | -24% | 662k | 2.41 |
|
| Spar (SGRP) | 0.0 | $1.6M | -24% | 662k | 2.41 |
|
| Eledon Pharmaceuticals (ELDN) | 0.0 | $1.6M | NEW | 600k | 2.64 |
|
| Eledon Pharmaceuticals (ELDN) | 0.0 | $1.6M | NEW | 600k | 2.64 |
|
| Altisource Portfolio Solns S Reg Shs (ASPS) | 0.0 | $1.5M | 1.1M | 1.41 |
|
|
| Altisource Portfolio Solns S Reg Shs (ASPS) | 0.0 | $1.5M | 1.1M | 1.41 |
|
|
| Unicycive Therapeutics (UNCY) | 0.0 | $1.4M | -15% | 2.8M | 0.50 |
|
| Unicycive Therapeutics (UNCY) | 0.0 | $1.4M | -15% | 2.8M | 0.50 |
|
| Anebulo Pharmaceuticals (ANEB) | 0.0 | $1.4M | 511k | 2.73 |
|
|
| Anebulo Pharmaceuticals (ANEB) | 0.0 | $1.4M | 511k | 2.73 |
|
|
| Instil Bio Com New (TIL) | 0.0 | $1.3M | 127k | 10.29 |
|
|
| Instil Bio Com New (TIL) | 0.0 | $1.3M | 127k | 10.29 |
|
|
| Aileron Therapeutics Com New (ALRN) | 0.0 | $1.3M | +82% | 464k | 2.77 |
|
| Aileron Therapeutics Com New (ALRN) | 0.0 | $1.3M | +82% | 464k | 2.77 |
|
| Lazydays Hldgs (GORV) | 0.0 | $1.3M | NEW | 500k | 2.54 |
|
| Lazydays Hldgs (GORV) | 0.0 | $1.3M | NEW | 500k | 2.54 |
|
| Verastem Com New (VSTM) | 0.0 | $1.2M | NEW | 400k | 2.98 |
|
| Verastem Com New (VSTM) | 0.0 | $1.2M | NEW | 400k | 2.98 |
|
| Strata Skin Sciences | 0.0 | $933k | NEW | 304k | 3.07 |
|
| Strata Skin Sciences | 0.0 | $933k | NEW | 304k | 3.07 |
|
| Kiora Pharmaceuticals Com New | 0.0 | $887k | NEW | 211k | 4.20 |
|
| Perfect Corp Cl A Ord Shs (PERF) | 0.0 | $847k | +109% | 419k | 2.02 |
|
| Perfect Corp Cl A Ord Shs (PERF) | 0.0 | $847k | +109% | 419k | 2.02 |
|
| Reneo Pharmaceuticals (RPHM) | 0.0 | $846k | NEW | 548k | 1.54 |
|
| Reneo Pharmaceuticals (RPHM) | 0.0 | $846k | NEW | 548k | 1.54 |
|
| Aprea Therapeutics Com New (APRE) | 0.0 | $837k | 206k | 4.07 |
|
|
| Aprea Therapeutics Com New (APRE) | 0.0 | $837k | 206k | 4.07 |
|
|
| Nikola Corp Com New | 0.0 | $819k | NEW | 100k | 8.19 |
|
| Nikola Corp Com New | 0.0 | $819k | NEW | 100k | 8.19 |
|
| Neuroone Med Technologies Com New (NMTC) | 0.0 | $761k | -20% | 951k | 0.80 |
|
| Neuroone Med Technologies Com New (NMTC) | 0.0 | $761k | -20% | 951k | 0.80 |
|
| Krystal Biotech Put Option (KRYS) | 0.0 | $716k | NEW | 3.9k | 183.64 |
|
| Krystal Biotech Put Option (KRYS) | 0.0 | $716k | NEW | 3.9k | 183.64 |
|
| Cutera Note 4.000% 6/0 (Principal) | 0.0 | $694k | 4.0M | 0.17 |
|
|
| Cutera Note 4.000% 6/0 (Principal) | 0.0 | $694k | 4.0M | 0.17 |
|
|
| Immatics *w Exp 07/01/202 (IMTXW) | 0.0 | $688k | -55% | 249k | 2.77 |
|
| Immatics *w Exp 07/01/202 (IMTXW) | 0.0 | $688k | -55% | 249k | 2.77 |
|
| Gossamer Bio (GOSS) | 0.0 | $623k | 673k | 0.93 |
|
|
| Gossamer Bio (GOSS) | 0.0 | $623k | 673k | 0.93 |
|
|
| B. Riley Financial (RILY) | 0.0 | $423k | -61% | 24k | 17.64 |
|
| B. Riley Financial (RILY) | 0.0 | $423k | -61% | 24k | 17.64 |
|
| Evoke Pharma Com New (EVOK) | 0.0 | $357k | 675k | 0.53 |
|
|
| Evoke Pharma Com New (EVOK) | 0.0 | $357k | 675k | 0.53 |
|
|
| Ladder Cap Corp Cl A (LADR) | 0.0 | $289k | 26k | 11.29 |
|
|
| Ladder Cap Corp Cl A (LADR) | 0.0 | $289k | 26k | 11.29 |
|
|
| Fortress Biotech Com New (FBIO) | 0.0 | $262k | -44% | 153k | 1.71 |
|
| Fortress Biotech Com New (FBIO) | 0.0 | $262k | -44% | 153k | 1.71 |
|
| Edgewise Therapeutics (EWTX) | 0.0 | $241k | 13k | 18.01 |
|
|
| Edgewise Therapeutics (EWTX) | 0.0 | $241k | 13k | 18.01 |
|
|
| An2 Therapeutics (ANTX) | 0.0 | $211k | 98k | 2.15 |
|
|
| An2 Therapeutics (ANTX) | 0.0 | $211k | 98k | 2.15 |
|
|
| Bm Technologies Cl A Com (BMTX) | 0.0 | $171k | 76k | 2.25 |
|
|
| Bm Technologies Cl A Com (BMTX) | 0.0 | $171k | 76k | 2.25 |
|
|
| Exagen (XGN) | 0.0 | $108k | -20% | 59k | 1.82 |
|
| Exagen (XGN) | 0.0 | $108k | -20% | 59k | 1.82 |
|
| Lucid Diagnostics (LUCD) | 0.0 | $104k | -15% | 126k | 0.82 |
|
| Lucid Diagnostics (LUCD) | 0.0 | $104k | -15% | 126k | 0.82 |
|
| TransAct Technologies Incorporated (TACT) | 0.0 | $76k | -15% | 20k | 3.77 |
|
| TransAct Technologies Incorporated (TACT) | 0.0 | $76k | -15% | 20k | 3.77 |
|
| Aptose Biosciences (APTO) | 0.0 | $59k | -12% | 77k | 0.76 |
|
| Aptose Biosciences (APTO) | 0.0 | $59k | -12% | 77k | 0.76 |
|
| Guardforce Ai *w Exp 10/01/202 (GFAIW) | 0.0 | $30k | 154k | 0.20 |
|
|
| Guardforce Ai *w Exp 10/01/202 (GFAIW) | 0.0 | $30k | 154k | 0.20 |
|
|
| Renalytix Ads (RNLX) | 0.0 | $27k | 118k | 0.23 |
|
|
| Renalytix Ads (RNLX) | 0.0 | $27k | 118k | 0.23 |
|
|
| Tc Biopharm Holdings *w Exp 02/10/202 (TCBPW) | 0.0 | $2.9k | 235k | 0.01 |
|
|
| Tc Biopharm Holdings *w Exp 02/10/202 (TCBPW) | 0.0 | $2.9k | 235k | 0.01 |
|
Past Filings by Nantahala Capital Management
SEC 13F filings are viewable for Nantahala Capital Management going back to 2011
- Nantahala Capital Management 2024 Q2 amended filed Aug. 20, 2024
- Nantahala Capital Management 2024 Q2 filed Aug. 14, 2024
- Nantahala Capital Management 2024 Q1 filed May 15, 2024
- Nantahala Capital Management 2023 Q4 amended filed Feb. 15, 2024
- Nantahala Capital Management 2023 Q4 filed Feb. 14, 2024
- Nantahala Capital Management 2023 Q3 filed Nov. 14, 2023
- Nantahala Capital Management 2023 Q2 filed Aug. 14, 2023
- Nantahala Capital Management 2023 Q1 filed May 15, 2023
- Nantahala Capital Management 2022 Q4 filed Feb. 14, 2023
- Nantahala Capital Management 2022 Q3 filed Nov. 10, 2022
- Nantahala Capital Management 2022 Q2 filed Aug. 15, 2022
- Nantahala Capital Management 2022 Q1 filed May 13, 2022
- Nantahala Capital Management 2021 Q4 filed Feb. 14, 2022
- Nantahala Capital Management 2021 Q3 filed Nov. 15, 2021
- Nantahala Capital Management 2021 Q2 filed Aug. 16, 2021
- Nantahala Capital Management 2021 Q1 filed May 14, 2021